Abstract
Hyperthermia (HT) has been widely used as an adjuvant to chemotherapy in the treatment of ovarian cancer, it has pleiotropic effects on cellular processes involved in tumor growth and progression. Inducing cellular stress response through heat-shock proteins (HSPs) expression is one of the main hallmarks of HT. HSPs have been reported to trigger an immune activation. However, antitumor immune responses are often invalidated by immune evasion mechanisms such as the overexpression of the immunosuppressive PD-L1 and the loss of MHC class I expression.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
